
Updates on the Binding Site's ongoing collaboration with the iStopMM study
ASH 2021
Dr. Stephen Harding discusses the continued partnership with the Binding Site and Dr. Sigurdur Kristinsson at the University of Iceland. Dr. Kristinsson leads the iStopMM study, and the Binding Site have analyzed more than 75,000 samples from study participants. The recent results from the iStopMM study were featured in compelling abstracts at the ASH Conference on December 2021. More updates to follow soon when the iStopMM study will begin using the Mass Spectrometry (EXENT) methodology for more sensitive testing for MGUS and SMM.
Learn More about the Binding Site and iStopMM:
https://www.bindingsite.com/en/the-science/istopmm/study-background
Learn More about iStopMM:
https://www.myeloma.org/black-swan-research-initiative/istopmm
Previous Post
Screening for Monoclonal Gammopathy of Undetermined Significance: First Results from the iStopMM Study
Next Post
What is multiple myeloma?